The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
29-Sep-16
$628 million
Target:
van Gansewinkel Groep BV
Acquiror:
Shanks Group plc
Advised Shanks Group plc, a leading international waste to product business, on the proposed merger with van Gansewinkel Groep BV, one of the leading waste management service providers, recyclers and suppliers of high-quality secondary raw materials in the Benelux region.
28-Jun-16
$NA
Target:
US rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
17-Jun-16
$310 million
Target:
Dobbies Garden Centres
Acquiror:
Investor group led by Midlothian Capital Partners and Hattington Capital
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of Dobbies Garden Centres to an investor group led by Midlothian Capital Partners and Hattington Capital
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
10-Jun-16
$NA
Target:
Giraffe restaurants
Acquiror:
Boparan Private Office
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of the Giraffe casual dining restaurant chain to the Boparan Private Office, the private investment vehicle of the British businessman Ranjit Boparan
25-Apr-16
$3.4 billion
Target:
Divestment assets of Ball and Rexam
Acquiror:
Ardagh Group SA
Advised Ball Corporation on the acquisition of Rexam plc and provided a fairness opinion to the Board of Directors of Ball Corporation on the sale of select metal beverage can assets in Europe, Brazil and the United States to satisfy certain regulatory requirements in connection with its proposed acquisition of Rexam
07-Apr-16
$105 million
Target:
Wireless Infrastructure Group
Acquiror:
3i Infrastructure plc
Advised 3i Infrastructure plc, a leading UK listed investor in infrastructure businesses and assets, on its acquisition of a 36% economic interest in Wireless Infrastructure Group, the UK’s 2nd largest independent telecommunications tower company
01-Dec-15
$164 million
Target:
Incotec Group BV
Acquiror:
Croda International Plc
Advised Croda International Plc, a leading UK listed global specialty chemicals producer, on its acquisition of Incotec Group BV, a Netherlands based provider of seed enhancement technologies
01-Dec-15
$NA
Target:
Allied Healthcare
Acquiror:
AURELIUS Investments
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
02-Nov-15
$NA
Target:
Reaction Engines Limited
Acquiror:
BAE Systems plc
Advised Reaction Engines Limited, a privately-held company located in the United Kingdom, on a strategic investment by BAE Systems plc, a leading defense, security and aerospace company based in the United Kingdom, to accelerate the company’s development of a new aerospace engine class
28-Oct-15
$NA
Target:
DataLase Ltd
Acquiror:
Sato Holdings Corporation
Advised Sato Holdings Corporation, a leading global provider of Auto-ID solutions, on its acquisition of a significant minority stake in DataLase Ltd, a UK-based provider of materials for laser coding and marking of products and packaging
14-Oct-15
$330 million
Target:
Professional Service Industries, Inc.
Acquiror:
Intertek Group plc
Advised Intertek Group plc, a leading quality solutions provider to industries worldwide, on its $330 million acquisition of Professional Service Industries, Inc. (“PSI”), a leading US based provider of testing and assurance services to commercial and civil construction markets
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
02-Jun-15
$NA
Target:
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Acquiror:
Perrigo Company plc
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
21-Apr-15
$NA
Target:
Tate & Lyle plc
Acquiror:
Archer Daniels Midland Company
Advised Tate & Lyle plc, a leading provider of ingredients and solutions to the food, beverage and other industries, on the re-alignment of Eaststarch C.V., its 50:50 corn wet milling joint venture in Europe with Archer Daniels Midland Company
30-Mar-15
$950 million
Target:
Quindell plc’s Professional Services Division
Acquiror:
Slater and Gordon
Advised Slater and Gordon Limited, an ASX-listed international consumer law firm, on the acquisition of Quindell plc’s Professional Services Division, the UK’s leading personal injury law firm operating across the claims value chain, and associated A$890 million equity and A$375 million debt raisings
27-Mar-15
$1.4 billion
Target:
AA plc
Advised AA plc, the UK’s leading roadside assistance provider, on the refinancing of its high yield bond and PIK instrument
24-Feb-15
$NA
Target:
Azelis Group (majority owned by 3i)
Acquiror:
Funds advised by Apax Partners
Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners
19-Feb-15
$8.4 billion
Target:
Rexam plc
Acquiror:
Ball Corporation
Advised Ball Corporation, a leading manufacturer of metal packaging products for the global beverage, food, personal care and household products industries as well as a provider of systems and technologies for the aerospace industry, on the acquisition of Rexam plc, a leading beverage can manufacturer